当前位置:循环首页>正文

[SCC2007]Pharmacogenomics of cardiovascular drugs Shu-Feng Zhou

作者:国际循环网   日期:2007/5/23 9:38:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

Current concepts in drug therapy for cardiovascular diseases often attempt drug treatment of large patient populations as only one group, irrespective of the potential for individual, genetically based differences in drug response. It is well recognized that most cardiovascular medications exhibit wide inter-patient variability in their efficacy and toxicity.

    School of Life Sciences, Faculty of Sciences, Queensland University of Technology, 2 George Street, GPO Box 2434, Brisbane, Queensland 4001, Australia.

    Current concepts in drug therapy for cardiovascular diseases often attempt drug treatment of large patient populations as only one group, irrespective of the potential for individual, genetically based differences in drug response. It is well recognized that most cardiovascular medications exhibit wide inter-patient variability in their efficacy and toxicity. Pharmacogenetics is the study of the influence of genetic factors in the individual variation in drug response, whereas pharmacogenomics is a more global definition and entails the study of the entire spectrum (network) of genes and their contribution to variability in drug efficacy and toxicity using genome-wide approaches Pharmacogenomic analysis can identify disease susceptibility genes representing potential new drug targets and focus effective therapy on smaller patient subpopulations which although demonstrating the same disease phenotype are characterized by distinct genetic profiles. 

    Evidence is accumulating to indicate that responses to cardiovascular drugs are at least partly under genetic control. Pharmacogenetics mostly relies on associations between a specific genetic marker like single nucleotide polymorphisms (SNPs), either alone or arranged in a specific linear order on a certain chromosomal region (haplotypes), and a particular response to drugs. Numerous genes, in particular those encoding PhasA I and II drug metabolizing enzymes (e.g. CYPs and UGTs), drug transporters (e.g. MDR1 and MRPs) and drug targets (e.g. ADRB1-3), have been identified to play a role in response to many cardiovascular drugs.  Recently, for instance, associations have been reported between specific alleles of the CYP2C9 gene and the blood clotting response to warfarin. Several SNPs in NR1I2 (PXR) gene leads to altered clearance of nifedipine.

    Ethnicity is an important variable contributing to inter-individual variability in response to cardiovascular drugs. The frequency of functional SNPs varies widely between ethnic groups and the Asian population is no exception to this. However, most of the current literature is concerned with polymorphisms in Caucasians and African-Americans, whereas the data in Asian populations are scant. In recent years, we have investigated the polymorphisms in a number of genes encoding Phase I and II drug metabolizing enzymes including CYP1A1, CYP3A4, CYP3A5, GSTM1, GSTP1, NAT2, NR1I2 (PXR), UGT1A1 and TPMT and MDR1 in Chinese population. Significant differences in the frequencies of common alleles encoding these proteins have been observed between Chinese and other ethnic groups. As such, dose requirements of certain cardiovascular drugs may not be optimal for our population and a second look at the factors responsible for this difference is necessary.

    Thus far, most pharmacogenetic studies have been limited to a priori selected candidate genes due to restricted genotyping and analytical capacities. Thanks to the large number of SNPs now available in the public domain through the SNP Consortium and the newly developed technologies (high throughput genotyping, bioinformatics software), it is now possible to interrogate more than 200,000 SNPs distributed over the entire human genome. All of this will lead to novel approaches in drug discovery, individualized dosing of cardiovascular medications, and new insights into cardiovascular disease susceptibility and prevention. 

版面编辑:admin


SCC2007

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530